Literature DB >> 31561176

Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

Zhaomin Xu1, Adan Z Becerra2, Carla F Justiniano1, Christopher T Aquina1, Fergal J Fleming1, Francis P Boscoe3, Maria J Schymura3, Abdulrahman K Sinno4, Jessica Chaoul5, Gary R Morrow6, Lori Minasian7, Sarah M Temkin8.   

Abstract

BACKGROUND: We examined factors associated with postoperative complications, 1-year overall and cancer-specific survival after epithelial ovarian cancer (EOC) diagnosis.
METHODS: Patients who underwent surgery for EOC between 2004 and 2013 were included. Multivariable models analyzed postoperative complications, overall survival, and cancer-specific survival.
RESULTS: Among 5223 patients, surgical complications were common. Postoperative complications correlated with increased odds of overall and disease-specific survival at 1 y. Receipt of chemotherapy was similar among women with and without postoperative complications and was independently associated with a reduction in the hazard of overall and disease-specific death at 1-year. Extensive pelvic and upper abdomen surgery resulted in 2.26 times the odds of postoperative complication, but was associated with longer 1-year overall 0.53 (0.35, 0.82) and disease-specific survival 0.54 (0.34, 0.85).
CONCLUSIONS: Although extent of surgery was associated with complications, the survival benefit from comprehensive surgery offset the risk. Tailored surgical treatment for women with EOC may improve outcomes.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Operative; Outcomes research; Ovarian neoplasms; Surgical procedures

Mesh:

Year:  2019        PMID: 31561176      PMCID: PMC6917987          DOI: 10.1016/j.jss.2019.08.027

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  29 in total

1.  Defining the limits of radical cytoreductive surgery for ovarian cancer.

Authors:  Jason D Wright; Sharyn N Lewin; Israel Deutsch; William M Burke; Xuming Sun; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  Gynecol Oncol       Date:  2011-09-28       Impact factor: 5.482

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 3.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

4.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

5.  Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients.

Authors:  Trine Lembrecht Jørgensen; Sandra Teiblum; Merete Paludan; Laurids Østergaard Poulsen; Anni Young Stensgård Jørgensen; Karin Herskind Bruun; Jesper Hallas; Jørn Herrstedt
Journal:  Gynecol Oncol       Date:  2012-07-16       Impact factor: 5.482

6.  Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.

Authors:  Ryan J Spencer; Kari E Hacker; Jennifer J Griggs; Laurel W Rice; R Kevin Reynolds; Shitanshu Uppal
Journal:  Obstet Gynecol       Date:  2017-08       Impact factor: 7.661

7.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

8.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

9.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

10.  A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model.

Authors:  Giovanni D Aletti; Antonio Santillan; Eric L Eisenhauer; Jae Hu; Giacomo Aletti; Karl C Podratz; Robert E Bristow; Dennis S Chi; William A Cliby
Journal:  Gynecol Oncol       Date:  2007-06-28       Impact factor: 5.482

View more
  5 in total

1.  Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Christa D Niehot; Heleen J van Beekhuizen
Journal:  J Gynecol Oncol       Date:  2022-06-07       Impact factor: 4.756

2.  The Influence of the Preoperative Status on the Risk of Postoperative Complications After Cytoreductive Surgery for Advanced-stage Ovarian Cancer.

Authors:  Laura Iliescu; Camelia Diaconu; Nicolae Bacalbasa; Irina Balescu; Mihai Dimitriu; Simona Dima; Mihaela Vilcu; Iulian Brezean
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

Review 3.  Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction.

Authors:  Mackenzie Cummings; Olivia Nicolais; Mark Shahin
Journal:  Diagnostics (Basel)       Date:  2022-04-14

4.  Factors Predicting 30-Day Grade IIIa-V Clavien-Dindo Classification Complications and Delayed Chemotherapy Initiation after Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Prospective Cohort Study.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Helena C van Doorn; Heleen J van Beekhuizen
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

5.  Lin28A Regulates Stem-like Properties of Ovarian Cancer Cells by Enriching RAN and HSBP1 mRNA and Up-regulating its Protein Expression.

Authors:  Yancheng Zhong; Lanqin Cao; Haotian Ma; Qian Wang; Pingpin Wei; Juan Yang; Yuqing Mo; Lihua Cao; Cijun Shuai; Shuping Peng
Journal:  Int J Biol Sci       Date:  2020-04-15       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.